Amgen Inc.
AMGNAmgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Drugs in Pipeline
282
Phase 3 Programs
134
Upcoming Catalysts
26
Next Catalyst
This month
Market Overview
Stock performance and key metrics
26 upcoming, 2 past
How AMGN's past catalysts played out
Lumakras
Sotorasib
KRAS G12C NSCLC
Risendronate
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
MP-376 (Levofloxacin Solution for Inhalation)
Cystic Fibrosis
Epoetin alfa RB
Nephrology
Actonel®
Osteoporosis
De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease
Background Statin Therapy
Dyslipidemia
ABP 938
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Apremilast 30mg
Psoriatic Arthritis
Cystagon®
Cystinosis
60 mg denosumab
Low Bone Mass
darbepoetin alfa
Anemia
Recombinant Human Keratinocyte Growth Factor
Stomatitis
Best Supportive Care
Multiple Myeloma
mFOLFOX6
Gastric Cancer
Zoledronic Acid
Bone Metastases
Denosumab
Osteoporosis
Romosozumab 90 mg/mL
Postmenopausal Osteoporosis
Oxaliplatin Based Chemotherapy
Colorectal Cancer
Denosumab (CP2)
Postmenopausal Osteoporosis
Ustekinumab
Psoriasis
Topical treatments or phototherapy
Plaque Psoriasis
Standard Chemotherapy
Cancer
Anakinra (Kineret®)
Rheumatoid Arthritis
etanercept pre-filled syringe subcutaneous injection
Rheumatoid Arthritis
Darbepoetin alfa - 2.25 mcg/kg
Anemia
Aranesp® (darbepoetin alfa)
Kidney Disease
Teprotumumab
Thyroid Eye Disease
1=Etanercept
Psoriasis
AMG 386
Ovarian Cancer
Non-steroidal aromatase inhibitor therapy
Breast Cancer
ABP 206
Melanoma
Pegloticase
Uncontrolled Gout
Statin therapy
Coronary Artery Disease (CAD)
Ibuprofen/famotidine
Ulcer
pegfilgrastim
Breast Cancer
interferon γ-1b
Friedreich's Ataxia
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
Inebilizumab
IgG4 Related Disease
Ibandronate
Postmenopausal Osteoporosis
ABP 710
Arthritis, Rheumatoid
Sotorasib
Non-small Cell Lung Cancer
Darbepoetin alpha
Myelodysplastic Syndrome
AMG 510
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Xaluritamig
Metastatic Castration-resistant Prostate Cancer
ABP 501
Arthritis, Rheumatoid
Denosumab (AMG 162)
Postmenopausal Osteoporosis
Erenumab Dose 1
Migraine
Etanercept / Autoinjector A
Rheumatoid Arthritis
Olpasiran
Cardiovascular Disease
TAC
Breast Cancer
ABP 654
Plaque Psoriasis
Erenumab Dose 2
Migraine
Denosumab (for the open-label treatment phase)
Cancer
Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Romiplostim
Chemotherapy-induced Thrombocytopenia
Dazodalibep
Sjögren's Syndrome (SS)
Topical agents
Psoriasis
AMG 162
Postmenopausal Osteoporosis
Cinacalcet HCl
Kidney Disease
AMG 531
Thrombocytopenia
HPN-100
Cirrhosis
romosozumab HCP administration with PFS
Post-Menopausal Osteoporosis
Low-intensity chemotherapy regimen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Palifermin
Head and Neck Cancer
Apremilast tablet 20 mg
Ankylosing Spondyloarthritis
Bemarituzumab
Gastric Cancer
Etanercept
Rheumatoid Arthritis
Darbepoetin alfa and Epoetin alfa
Anemia
Apremilast 30 mg
Psoriatic Arthritis
alendronate
Osteoporosis
Erenumab
Migraine
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Etanercept Liquid
Rheumatoid Arthritis
Aeroquin
Cystic Fibrosis
Commercial Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
ABP 959
Paroxysmal Nocturnal Hemoglobinuria
Apremilast
Behçet's Disease
Atorvastatin
Hyperlipidemia
Carfilzomib
Multiple Myeloma
Etelcalcetide
Secondary Hyperparathyroidism
Omnipaque
Cardiovascular Disease
Evolocumab Pre-filled Syringe
Primary Hypercholesterolemia
Panitumumab
Metastatic Colorectal Cancer
Romozosumab
Postmenopausal Osteoporosis
50 mg Etanercept
Rheumatoid Arthritis
Cinacalcet
End Stage Renal Disease
Bisphosphonate
Osteogenesis Imperfecta
Ezetimibe
Hyperlipidemia
Epoetin alfa DT
Chronic Kidney Disease
Cystagon® (Cysteamine Bitartrate)
Cystinosis
Omitted Doxorubicin
Leukemia, Acute Lymphoblastic
Pegaspargase
Acute Lymphoblastic Leukemia
Levitra (Vardenafil, BAY38-9456)
Erectile Dysfunction
Buphenyl (NaPBA)
Urea Cycle Disorders
Evolocumab
Hyperlipidemia
Romosozumab
Postmenopausal Women With Osteoporosis
Rosuvastatin
Hyperlipidemia
MR prednisone
Rheumatoid Arthritis
darbepoetin alfa SF
Kidney Disease
FOLFIRI Regimen
Metastatic Colorectal Cancer
HZT-501
Osteoarthritis
Ivabradine
Postural Orthostatic Tachycardia Syndrome
Tarlatamab
Small Cell Lung Cancer
ARM 2
Recurrent and/or Metastatic Head and Neck Cancer
Melphalan
Multiple Myeloma
Avacopan
Vasculitis
Lurbinectedin
Small Cell Lung Cancer (SCLC)
Chemotherapy
Gastric Cancer
Sorafenib (Nexavar, BAY43-9006)
Thyroid Neoplasms
ABP 798
Arthritis, Rheumatoid
Trifluridine and Tipiracil
Colorectal Cancer (CRC)
Darbepoetin alpha (Aranesp)
Hematological Malignancies
ABP 980
Breast Cancer
Apremilast (CC-10004)
Behcet Syndrome
Rocatinlimab
Asthma
Talimogene laherparepvec
Melanoma
chemotherapy with LMWH - enoxaparin
Pancreatic Cancer
ABP 215
Non-small Cell Lung Cancer Metastatic
Vincrisitne
Leukemia, Acute Lymphoblastic
Denosumab 60 MG [Prolia]
Bone Density
Topical Therapy
Plaque Psoriasis
Lanadelumab
COVID-19
ABP 938 8 mg
Neovascular Age-related Macular Degeneration
FOLFOX regimen
Metastatic Colorectal Cancer
RP103
Cystinosis
Romosozumab Prefilled Syringe
Bone Density, Low
Blinatumomab
Acute Lymphoblastic Leukemia
AMG 073
Secondary Hyperparathyroidism
Aranesp®
Kidney Disease
rHuEPO
Cancer
Apremilast 20mg
Psoriatic Arthritis
Evolocumab AMD
Primary Hypercholesterolemia
AMG 162 / Denosumab
Breast Cancer
Panitumumab + paclitaxel
Head and Neck Cancer
Panitumumab and CPT-11
Metastatic Colorectal Cancer
MEDI9929
Atopic Dermatitis
Amgen 386
Glioblastoma Multiforme
Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Unresectable Locally Advanced NSCLC
Inotuzumab
Acute Lymphoblastic Leukemia
MEDI9929 70 mg
Asthma
Subcutaneous Blinatumomab
CD19 Positive
Group A: Carfilzomib & Non-IMiD Regimen
Multiple Myeloma
Talimogene Laherparepvec (T-VEC)
Sarcoma
Oral Contraceptive Pills (OCPs)
Amenorrhea
Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
Temporomandibular Disorder
Vinblastine sulfate
HIV Infections
PEG asparaginase
Lymphoblastic Leukemia
AMG 102 and erlotinib
Carcinoma, Non-Small-Cell Lung
Anvumetostat
Advanced MTAP-null Solid Tumors
Panitumumab + FOLFOX (DP)
Metastatic Colorectal Cancer
CC10004
Psoriasis
Filgrastim-SD/01
Non-small Cell Lung Cancer
Mitozantrone
Non-Hodgkin's Lymphoma
Alendronate Effervescent Oral Tablet
Erosive Osteoarthritis
Pegfilgrastim (Neulasta)
Multiple Myeloma
Intervention A: Irinotecan; Oxaliplatin; Neulasta
Non-Small Cell Lung Cancer
Adecatumumab
Liver Metastases
AMG 531 (Romiplostim)
MDS
IV Bisphosphonates
Breast Cancer
AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
Breast Cancer
panitumumab, mytomicin C, 5-FU, radiation
Anal Squamous Cell Carcinoma
docetaxel + cyclophosphamide + pegfilgrastim
Female Breast Cancer
Darbepoetin alfa SC
Anemia
pegfilgrastim 12 mg
Lymphoma
T-VEC
Melanoma Stage III
5-Fluorouracil
Colorectal Cancer
Panitumumab (ABX-EGF)
Advanced Renal Cell Carcinoma
AMG 853
Asthma
epratuzumab
Non-Hodgkin's Lymphoma
cinacalcet (AMG 073)
Secondary Hyperparathyroidism
Antizol
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
N-Plate / romiplostim
Myelodysplastic Syndromes
VIB7734
Lupus Erythematosus, Systemic
Modified FOLFOX6
Advanced Solid Tumors
AMG 827
Asthma
IV Bisphosphonate q 4 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Pegsunercept (PEG sTNF-RI)
Rheumatoid Arthritis
MP-376
Cystic Fibrosis (CF)
Teriparatide
Low Bone Mineral Density
CCX140-B
Diabetic Nephropathy
AMG 102 at 10 mg/kg
Advanced Renal Cell Carcinoma
AMG 655
Metastatic Colorectal Cancer
BUPHENYL®
Urea Cycle Disorders
CCX-354-C
Rheumatoid Arthritis
100 mg AMG 162
Osteoporosis
filgrastim
Sarcoma
ABX-EGF
Non-small Cell Lung Cancer
VIB4920
Sjögren's Syndrome
Belatacept
Allografts
Conatumumab
Colon Cancer
AMG 714
Psoriasis
AMG 719
Rheumatoid Arthritis
AMG 732
Thyroid Eye Disease
Abrilumab
Ulcerative Colitis
Brodalumab
Rheumatoid Arthritis
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Anemia
Tezepelumab Dose 1
Chronic Spontaneous Urticaria
Cysteamine Bitartrate
Inherited Mitochondrial Disease, Including Leigh Syndrome
Recombinant Human Erythropoietin
Breast Cancer
CCX168
Vasculitis
ABX-EGF (panitumumab)
Metastatic Colorectal Cancer
IDE397
MTAP-null Non-Small-Cell Lung Cancer
recombinant human erythropoietin (rHuEPO)
Gynecological Malignancies
AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
HZN-1116
Sjogren's Syndrome
Investigator's Choice Chemotherapy
High-risk Diffuse Large B-Cell Lymphoma
AMG 193
MTAP-deleted NSCLC
Systemic AMG 108
Osteoarthritis
Blinatumomab (MT103)
Acute Lymphoblastic Leukemia
anakinra
Rheumatoid Arthritis
AMG 317 75 mg
Asthma
Liatermin
Parkinson's Disease
Daxdilimab
Alopecia Areata
AMG 151
Diabetes Mellitus
Intra-articular metHuIL-1ra (anakinra)
Osteoarthritis
IV iron dextran
Anemia
Neulasta
Breast Cancer
CC-11050
Cutaneous Lupus Erythematosus
Erenumab PFS
Migraine
AMG 102 at 20 mg/kg
Advanced Malignant Glioma
CCX 354-C
Rheumatoid Arthritis
AMG 706
Gastrointestinal Cancer
AMG 337
Stomach Neoplasms
Apremilast 10mg
Psoriasis
AMG 386 10mg/kg
Gastrointestinal Cancer
Naproxen
Bone Pain in Stage I - III Breast Cancer
CC-10004
Psoriasis
Oprozomib
Multiple Myeloma
Previous denosumab
Low Bone Mass
Sensipar (Cinacalcet HCl)
Secondary Hyperparathyroidism
Cytarabine
Lymphoma
AMG 301
Chronic Migraine or Episodic Migraine
AMG 108
Rheumatoid Arthritis
Lodotra
Asthma
CCX282-B
Crohn's Disease
AMG 223
End Stage Renal Disease
NaPBA
Urea Cycle Disorders
Motesanib diphosphate
Lung Cancer
AMG 102
Cancer
RCHOP
Richter Syndrome
Romidepsin
Peripheral T Cell Lymphoma
Epirubicin, Cisplatin, Capecitabine, Panitumumab
Stomach Neoplasms
RAD
Multiple Myeloma
Interferon gamma-1b
Acute Myeloid Leukemia
AMG 334
Post-Traumatic Headache
CPT-11
Non Small Cell Lung Cancer
liposomal cytarabine
Primary Disease
5FU
Squamous Cell Carcinoma of Head and Neck
CEEP regimen
Lymphoma
Blinatumomab 9ug
Acute Lymphoblastic Leukemia
Mini-CVD
B-cell Acute Lymphoblastic Leukemia
standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
Acute Myeloid Leukemia
Consolidation with 4 cycles of CarCyDex
Multiple Myeloma
TALIMOGENE LAHERPAREPVEC (TVEC)
Melanoma
Myocet
Breast Cancer
Aranesp
Prostate Cancer
FOLFOXIRI + Panitumumab
Metastatic Colorectal Cancer
Panitumumab+irinotecan
Metastatic Colorectal Cancer
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Multiple Myeloma
Maintenance Chemotherapy
Metastatic Colorectal Cancer
5Fluorouracil
Rectal Cancer
epirubicin hydrochloride
Breast Cancer
Randomization to No Panitumumab
Metastatic Colorectal Cancer
Trebananib
Advanced Renal Cell Carcinoma
Doxycycline 50Mg Tablet
Skin Toxicity
leucovorin calcium
Mucinous Adenocarcinoma of the Colon
r-metHuLeptin
HAART-induced Lipodystrophy and Metabolic Syndrome
Dapagliflozin 10Mg Tab
HFrEF
AMG 557/MEDI5872
Primary Sjögren's Syndrome
Doxorubicin hydrochloride (liposomal)
Sarcoma, Kaposi
Injection of Pegfilgrastim
Lymphoma
Acyclovir
Metastatic Castration-resistant Prostate Cancer
Denosumab Q4W
Multiple Myeloma
bemarituzumab, paclitaxel, ramucirumab
Metastatic Gastro-esophageal Adenocarcinoma
KRdD followed by auto-HCT
Multiple Myeloma
tacrolimus (standard GVHD prophylaxis)
Graft Versus Host Disease
R-CHOEP14x6+HD-AraC+HD-Mtx
Diffuse Large B-Cell Lymphoma
Diphenhydramine
Multiple Myeloma
Rozibafusp Alfa
Systemic Lupus Erythematosus (SLE)
AMG 509
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumakras Sotorasib | Approved | KRAS G12C NSCLC | Fast TrackBreakthrough | Patent 2040 |
Risendronate | Phase 3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | - | - |
MP-376 (Levofloxacin Solution for Inhalation) | Phase 3 | Cystic Fibrosis | - | - |
Epoetin alfa RB | Phase 3 | Nephrology | - | - |
Actonel® | Phase 3 | Osteoporosis | - | - |
De Novo Administration of Darbepoetin Alfa | Phase 3 | Chronic Kidney Disease | - | - |
Background Statin Therapy | Phase 3 | Dyslipidemia | - | - |
ABP 938 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | - | - |
Apremilast 30mg | Phase 3 | Psoriatic Arthritis | - | - |
Cystagon® | Phase 3 | Cystinosis | - | - |
60 mg denosumab | Phase 3 | Low Bone Mass | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
Recombinant Human Keratinocyte Growth Factor | Phase 3 | Stomatitis | - | - |
Best Supportive Care | Phase 3 | Multiple Myeloma | - | - |
mFOLFOX6 | Phase 3 | Gastric Cancer | - | - |
Zoledronic Acid | Phase 3 | Bone Metastases | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
Romosozumab 90 mg/mL | Phase 3 | Postmenopausal Osteoporosis | - | - |
Oxaliplatin Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
Denosumab (CP2) | Phase 3 | Postmenopausal Osteoporosis | - | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Topical treatments or phototherapy | Phase 3 | Plaque Psoriasis | - | - |
Standard Chemotherapy | Phase 3 | Cancer | - | - |
Anakinra (Kineret®) | Phase 3 | Rheumatoid Arthritis | - | - |
etanercept pre-filled syringe subcutaneous injection | Phase 3 | Rheumatoid Arthritis | - | - |
Darbepoetin alfa - 2.25 mcg/kg | Phase 3 | Anemia | - | - |
Aranesp® (darbepoetin alfa) | Phase 3 | Kidney Disease | - | - |
Teprotumumab | Phase 3 | Thyroid Eye Disease | - | - |
1=Etanercept | Phase 3 | Psoriasis | - | - |
AMG 386 | Phase 3 | Ovarian Cancer | - | - |
Non-steroidal aromatase inhibitor therapy | Phase 3 | Breast Cancer | - | - |
ABP 206 | Phase 3 | Melanoma | - | - |
Pegloticase | Phase 3 | Uncontrolled Gout | - | - |
Statin therapy | Phase 3 | Coronary Artery Disease (CAD) | - | - |
Ibuprofen/famotidine | Phase 3 | Ulcer | - | - |
pegfilgrastim | Phase 3 | Breast Cancer | - | - |
interferon γ-1b | Phase 3 | Friedreich's Ataxia | - | - |
Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
Inebilizumab | Phase 3 | IgG4 Related Disease | - | - |
Ibandronate | Phase 3 | Postmenopausal Osteoporosis | - | - |
ABP 710 | Phase 3 | Arthritis, Rheumatoid | - | - |
Sotorasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Darbepoetin alpha | Phase 3 | Myelodysplastic Syndrome | - | - |
AMG 510 | Phase 3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | - | - |
ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | - | - |
Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
ABP 501 | Phase 3 | Arthritis, Rheumatoid | - | - |
Denosumab (AMG 162) | Phase 3 | Postmenopausal Osteoporosis | - | - |
Erenumab Dose 1 | Phase 3 | Migraine | - | - |
Etanercept / Autoinjector A | Phase 3 | Rheumatoid Arthritis | - | - |
Olpasiran | Phase 3 | Cardiovascular Disease | - | - |
TAC | Phase 3 | Breast Cancer | - | - |
ABP 654 | Phase 3 | Plaque Psoriasis | - | - |
Erenumab Dose 2 | Phase 3 | Migraine | - | - |
Denosumab (for the open-label treatment phase) | Phase 3 | Cancer | - | - |
Cysteamine Bitartrate Delayed-release Capsules | Phase 3 | Cystinosis | - | - |
Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | - | - |
Topical agents | Phase 3 | Psoriasis | - | - |
AMG 162 | Phase 3 | Postmenopausal Osteoporosis | - | - |
Cinacalcet HCl | Phase 3 | Kidney Disease | - | - |
AMG 531 | Phase 3 | Thrombocytopenia | - | - |
HPN-100 | Phase 3 | Cirrhosis | - | - |
romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis | - | - |
Low-intensity chemotherapy regimen | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | - | - |
Palifermin | Phase 3 | Head and Neck Cancer | - | - |
Apremilast tablet 20 mg | Phase 3 | Ankylosing Spondyloarthritis | - | - |
Bemarituzumab | Phase 3 | Gastric Cancer | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Darbepoetin alfa and Epoetin alfa | Phase 3 | Anemia | - | - |
Apremilast 30 mg | Phase 3 | Psoriatic Arthritis | - | - |
alendronate | Phase 3 | Osteoporosis | - | - |
Erenumab | Phase 3 | Migraine | - | - |
Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | - | - |
Etanercept Liquid | Phase 3 | Rheumatoid Arthritis | - | - |
Aeroquin | Phase 3 | Cystic Fibrosis | - | - |
Commercial Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
ABP 959 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Apremilast | Phase 3 | Behçet's Disease | - | - |
Atorvastatin | Phase 3 | Hyperlipidemia | - | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - | - |
Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | - | - |
Omnipaque | Phase 3 | Cardiovascular Disease | - | - |
Evolocumab Pre-filled Syringe | Phase 3 | Primary Hypercholesterolemia | - | - |
Panitumumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Romozosumab | Phase 3 | Postmenopausal Osteoporosis | - | - |
50 mg Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Cinacalcet | Phase 3 | End Stage Renal Disease | - | - |
Bisphosphonate | Phase 3 | Osteogenesis Imperfecta | - | - |
Ezetimibe | Phase 3 | Hyperlipidemia | - | - |
Epoetin alfa DT | Phase 3 | Chronic Kidney Disease | - | - |
Cystagon® (Cysteamine Bitartrate) | Phase 3 | Cystinosis | - | - |
Omitted Doxorubicin | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Pegaspargase | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Levitra (Vardenafil, BAY38-9456) | Phase 3 | Erectile Dysfunction | - | - |
Buphenyl (NaPBA) | Phase 3 | Urea Cycle Disorders | - | - |
Evolocumab | Phase 3 | Hyperlipidemia | - | - |
Romosozumab | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
Rosuvastatin | Phase 3 | Hyperlipidemia | - | - |
MR prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
darbepoetin alfa SF | Phase 3 | Kidney Disease | - | - |
FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
HZT-501 | Phase 3 | Osteoarthritis | - | - |
Ivabradine | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
Tarlatamab | Phase 3 | Small Cell Lung Cancer | OrphanFast TrackBreakthrough | |
ARM 2 | Phase 3 | Recurrent and/or Metastatic Head and Neck Cancer | - | - |
Melphalan | Phase 3 | Multiple Myeloma | - | - |
Avacopan | Phase 3 | Vasculitis | - | - |
Lurbinectedin | Phase 3 | Small Cell Lung Cancer (SCLC) | - | - |
Chemotherapy | Phase 3 | Gastric Cancer | - | - |
Sorafenib (Nexavar, BAY43-9006) | Phase 3 | Thyroid Neoplasms | - | - |
ABP 798 | Phase 3 | Arthritis, Rheumatoid | - | - |
Trifluridine and Tipiracil | Phase 3 | Colorectal Cancer (CRC) | - | - |
Darbepoetin alpha (Aranesp) | Phase 3 | Hematological Malignancies | - | - |
ABP 980 | Phase 3 | Breast Cancer | - | - |
Apremilast (CC-10004) | Phase 3 | Behcet Syndrome | - | - |
Rocatinlimab | Phase 3 | Asthma | - | - |
Talimogene laherparepvec | Phase 3 | Melanoma | - | - |
chemotherapy with LMWH - enoxaparin | Phase 3 | Pancreatic Cancer | - | - |
ABP 215 | Phase 3 | Non-small Cell Lung Cancer Metastatic | - | - |
Vincrisitne | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Denosumab 60 MG [Prolia] | Phase 3 | Bone Density | - | - |
Topical Therapy | Phase 3 | Plaque Psoriasis | - | - |
Lanadelumab | Phase 3 | COVID-19 | - | - |
ABP 938 8 mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
FOLFOX regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
RP103 | Phase 3 | Cystinosis | - | - |
Romosozumab Prefilled Syringe | Phase 3 | Bone Density, Low | - | - |
Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
AMG 073 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Aranesp® | Phase 3 | Kidney Disease | - | - |
rHuEPO | Phase 3 | Cancer | - | - |
Apremilast 20mg | Phase 3 | Psoriatic Arthritis | - | - |
Evolocumab AMD | Phase 3 | Primary Hypercholesterolemia | - | - |
AMG 162 / Denosumab | Phase 3 | Breast Cancer | - | - |
Panitumumab + paclitaxel | Phase 2 | Head and Neck Cancer | - | - |
Panitumumab and CPT-11 | Phase 2 | Metastatic Colorectal Cancer | - | - |
MEDI9929 | Phase 2 | Atopic Dermatitis | - | - |
Amgen 386 | Phase 2 | Glioblastoma Multiforme | - | - |
Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta | Phase 2 | Unresectable Locally Advanced NSCLC | - | - |
Inotuzumab | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
MEDI9929 70 mg | Phase 2 | Asthma | - | - |
Subcutaneous Blinatumomab | Phase 2 | CD19 Positive | - | - |
Group A: Carfilzomib & Non-IMiD Regimen | Phase 2 | Multiple Myeloma | - | - |
Talimogene Laherparepvec (T-VEC) | Phase 2 | Sarcoma | - | - |
Oral Contraceptive Pills (OCPs) | Phase 2 | Amenorrhea | - | - |
Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments | Phase 2 | Temporomandibular Disorder | - | - |
Vinblastine sulfate | Phase 2 | HIV Infections | - | - |
PEG asparaginase | Phase 2 | Lymphoblastic Leukemia | - | - |
AMG 102 and erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Anvumetostat | Phase 2 | Advanced MTAP-null Solid Tumors | - | - |
Panitumumab + FOLFOX (DP) | Phase 2 | Metastatic Colorectal Cancer | - | - |
CC10004 | Phase 2 | Psoriasis | - | - |
Filgrastim-SD/01 | Phase 2 | Non-small Cell Lung Cancer | - | - |
Mitozantrone | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Alendronate Effervescent Oral Tablet | Phase 2 | Erosive Osteoarthritis | - | - |
Pegfilgrastim (Neulasta) | Phase 2 | Multiple Myeloma | - | - |
Intervention A: Irinotecan; Oxaliplatin; Neulasta | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Adecatumumab | Phase 2 | Liver Metastases | - | - |
AMG 531 (Romiplostim) | Phase 2 | MDS | - | - |
IV Bisphosphonates | Phase 2 | Breast Cancer | - | - |
AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) | Phase 2 | Breast Cancer | - | - |
panitumumab, mytomicin C, 5-FU, radiation | Phase 2 | Anal Squamous Cell Carcinoma | - | - |
docetaxel + cyclophosphamide + pegfilgrastim | Phase 2 | Female Breast Cancer | - | - |
Darbepoetin alfa SC | Phase 2 | Anemia | - | - |
pegfilgrastim 12 mg | Phase 2 | Lymphoma | - | - |
T-VEC | Phase 2 | Melanoma Stage III | - | - |
5-Fluorouracil | Phase 2 | Colorectal Cancer | - | - |
Panitumumab (ABX-EGF) | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 853 | Phase 2 | Asthma | - | - |
epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
cinacalcet (AMG 073) | Phase 2 | Secondary Hyperparathyroidism | - | - |
Antizol | Phase 2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | - | - |
N-Plate / romiplostim | Phase 2 | Myelodysplastic Syndromes | - | - |
VIB7734 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Modified FOLFOX6 | Phase 2 | Advanced Solid Tumors | - | - |
AMG 827 | Phase 2 | Asthma | - | - |
IV Bisphosphonate q 4 weeks | Phase 2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | - | - |
Pegsunercept (PEG sTNF-RI) | Phase 2 | Rheumatoid Arthritis | - | - |
MP-376 | Phase 2 | Cystic Fibrosis (CF) | - | - |
Teriparatide | Phase 2 | Low Bone Mineral Density | - | - |
CCX140-B | Phase 2 | Diabetic Nephropathy | - | - |
AMG 102 at 10 mg/kg | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 655 | Phase 2 | Metastatic Colorectal Cancer | - | - |
BUPHENYL® | Phase 2 | Urea Cycle Disorders | - | - |
CCX-354-C | Phase 2 | Rheumatoid Arthritis | - | - |
100 mg AMG 162 | Phase 2 | Osteoporosis | - | - |
filgrastim | Phase 2 | Sarcoma | - | - |
ABX-EGF | Phase 2 | Non-small Cell Lung Cancer | - | - |
VIB4920 | Phase 2 | Sjögren's Syndrome | - | - |
Belatacept | Phase 2 | Allografts | - | - |
Conatumumab | Phase 2 | Colon Cancer | - | - |
AMG 714 | Phase 2 | Psoriasis | - | - |
AMG 719 | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 732 | Phase 2 | Thyroid Eye Disease | - | - |
Abrilumab | Phase 2 | Ulcerative Colitis | - | - |
Brodalumab | Phase 2 | Rheumatoid Arthritis | - | - |
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Phase 2 | Anemia | - | - |
Tezepelumab Dose 1 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
Cysteamine Bitartrate | Phase 2 | Inherited Mitochondrial Disease, Including Leigh Syndrome | - | - |
Recombinant Human Erythropoietin | Phase 2 | Breast Cancer | - | - |
CCX168 | Phase 2 | Vasculitis | - | - |
ABX-EGF (panitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
IDE397 | Phase 2 | MTAP-null Non-Small-Cell Lung Cancer | - | - |
recombinant human erythropoietin (rHuEPO) | Phase 2 | Gynecological Malignancies | - | - |
AMG 951 (rhApo2L/TRAIL) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
HZN-1116 | Phase 2 | Sjogren's Syndrome | - | - |
Investigator's Choice Chemotherapy | Phase 2 | High-risk Diffuse Large B-Cell Lymphoma | - | - |
AMG 193 | Phase 2 | MTAP-deleted NSCLC | - | - |
Systemic AMG 108 | Phase 2 | Osteoarthritis | - | - |
Blinatumomab (MT103) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
anakinra | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 317 75 mg | Phase 2 | Asthma | - | - |
Liatermin | Phase 2 | Parkinson's Disease | - | - |
Daxdilimab | Phase 2 | Alopecia Areata | - | - |
AMG 151 | Phase 2 | Diabetes Mellitus | - | - |
Intra-articular metHuIL-1ra (anakinra) | Phase 2 | Osteoarthritis | - | - |
IV iron dextran | Phase 2 | Anemia | - | - |
Neulasta | Phase 2 | Breast Cancer | - | - |
CC-11050 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
Erenumab PFS | Phase 2 | Migraine | - | - |
AMG 102 at 20 mg/kg | Phase 2 | Advanced Malignant Glioma | - | - |
CCX 354-C | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 706 | Phase 2 | Gastrointestinal Cancer | - | - |
AMG 337 | Phase 2 | Stomach Neoplasms | - | - |
Apremilast 10mg | Phase 2 | Psoriasis | - | - |
AMG 386 10mg/kg | Phase 2 | Gastrointestinal Cancer | - | - |
Naproxen | Phase 2 | Bone Pain in Stage I - III Breast Cancer | - | - |
CC-10004 | Phase 2 | Psoriasis | - | - |
Oprozomib | Phase 2 | Multiple Myeloma | - | - |
Previous denosumab | Phase 2 | Low Bone Mass | - | - |
Sensipar (Cinacalcet HCl) | Phase 2 | Secondary Hyperparathyroidism | - | - |
Cytarabine | Phase 2 | Lymphoma | - | - |
AMG 301 | Phase 2 | Chronic Migraine or Episodic Migraine | - | - |
AMG 108 | Phase 2 | Rheumatoid Arthritis | - | - |
Lodotra | Phase 2 | Asthma | - | - |
CCX282-B | Phase 2 | Crohn's Disease | - | - |
AMG 223 | Phase 2 | End Stage Renal Disease | - | - |
NaPBA | Phase 2 | Urea Cycle Disorders | - | - |
Motesanib diphosphate | Phase 2 | Lung Cancer | - | - |
AMG 102 | Phase 2 | Cancer | - | - |
RCHOP | Phase 2 | Richter Syndrome | - | - |
Romidepsin | Phase 2 | Peripheral T Cell Lymphoma | - | - |
Epirubicin, Cisplatin, Capecitabine, Panitumumab | Phase 2 | Stomach Neoplasms | - | - |
RAD | Phase 2 | Multiple Myeloma | - | - |
Interferon gamma-1b | Phase 2 | Acute Myeloid Leukemia | - | - |
AMG 334 | Phase 2 | Post-Traumatic Headache | - | - |
CPT-11 | Phase 2 | Non Small Cell Lung Cancer | - | - |
liposomal cytarabine | Phase 2 | Primary Disease | - | - |
5FU | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
CEEP regimen | Phase 2 | Lymphoma | - | - |
Blinatumomab 9ug | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
Mini-CVD | Phase 2 | B-cell Acute Lymphoblastic Leukemia | - | - |
standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Consolidation with 4 cycles of CarCyDex | Phase 2 | Multiple Myeloma | - | - |
TALIMOGENE LAHERPAREPVEC (TVEC) | Phase 2 | Melanoma | - | - |
Myocet | Phase 2 | Breast Cancer | - | - |
Aranesp | Phase 2 | Prostate Cancer | - | - |
FOLFOXIRI + Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Panitumumab+irinotecan | Phase 2 | Metastatic Colorectal Cancer | - | - |
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Phase 2 | Multiple Myeloma | - | - |
Maintenance Chemotherapy | Phase 2 | Metastatic Colorectal Cancer | - | - |
5Fluorouracil | Phase 2 | Rectal Cancer | - | - |
epirubicin hydrochloride | Phase 2 | Breast Cancer | - | - |
Randomization to No Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Trebananib | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
Doxycycline 50Mg Tablet | Phase 2 | Skin Toxicity | - | - |
leucovorin calcium | Phase 2 | Mucinous Adenocarcinoma of the Colon | - | - |
r-metHuLeptin | Phase 2 | HAART-induced Lipodystrophy and Metabolic Syndrome | - | - |
Dapagliflozin 10Mg Tab | Phase 2 | HFrEF | - | - |
AMG 557/MEDI5872 | Phase 2 | Primary Sjögren's Syndrome | - | - |
Doxorubicin hydrochloride (liposomal) | Phase 2 | Sarcoma, Kaposi | - | - |
Injection of Pegfilgrastim | Phase 2 | Lymphoma | - | - |
Acyclovir | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Denosumab Q4W | Phase 2 | Multiple Myeloma | - | - |
bemarituzumab, paclitaxel, ramucirumab | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | - | - |
KRdD followed by auto-HCT | Phase 2 | Multiple Myeloma | - | - |
tacrolimus (standard GVHD prophylaxis) | Phase 2 | Graft Versus Host Disease | - | - |
R-CHOEP14x6+HD-AraC+HD-Mtx | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Diphenhydramine | Phase 2 | Multiple Myeloma | - | - |
Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
AMG 509 | Phase 1 | Prostate Cancer | Fast Track | - |
eosinophilic esophagitis
2 drugs in this indication
KRAS G12C NSCLC
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Prostate Cancer
1 drug in this indication
reduction of cardiovascular risk, prevention of first myocardial infarction or stroke
1 drug in this indication
Cardiovascular risk reduction, primary prevention of myocardial infarction and stroke
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
eosinophilic esophagitis (EoE), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP)
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke in patients with cardiovascular disease
1 drug in this indication
primary prevention of myocardial infarction and stroke
1 drug in this indication
rare disease
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke
1 drug in this indication
reduction of risk of first heart attack or stroke
1 drug in this indication
Obesity
1 drug in this indication
lung cancer
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
oncology
1 drug in this indication
rare kidney disease
1 drug in this indication
ANCA-associated vasculitis (AAV)
1 drug in this indication
Asthma with swallowing disorder
1 drug in this indication
Temporomandibular Disorder
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amgen Inc.'s drug pipeline?→
CatalystAlert tracks 282 drug candidates in Amgen Inc.'s (AMGN) pipeline across Phase 3, Phase 2, Phase 1, Approved. Its lead program is Risendronate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amgen Inc.'s next FDA catalyst?→
Amgen Inc.'s (AMGN) next tracked catalyst is a Phase 3 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMGN biotech catalysts?→
Add AMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amgen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.